Addenda Capital Inc. Cuts Stake in Pfizer Inc. $PFE

Addenda Capital Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 9.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 290,800 shares of the biopharmaceutical company’s stock after selling 31,579 shares during the quarter. Addenda Capital Inc.’s holdings in Pfizer were worth $7,241,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. State Street Corp raised its position in Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after buying an additional 2,786,098 shares during the last quarter. Northern Trust Corp raised its position in Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after buying an additional 869,175 shares during the last quarter. Fisher Asset Management LLC raised its position in Pfizer by 1.9% during the 3rd quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after buying an additional 897,786 shares during the last quarter. Legal & General Group Plc raised its position in Pfizer by 8.6% during the 3rd quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after buying an additional 3,296,415 shares during the last quarter. Finally, Amundi raised its position in Pfizer by 10.8% during the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock worth $1,096,380,000 after buying an additional 4,043,413 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on PFE shares. Morgan Stanley set a $27.00 price objective on shares of Pfizer and gave the stock a “positive” rating in a research report on Tuesday, March 17th. HSBC increased their price target on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Bank of America cut their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a report on Monday, December 15th. Barclays started coverage on shares of Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Finally, Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $28.19.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s deep oncology footprint and growing pipeline (small molecules, ADCs, immuno‑oncology), which could support revenue upside as Q1 results and late‑stage readouts approach. How Pfizer’s Oncology Portfolio Is Shaping Up Before Q1 Results
• Positive Sentiment: Company filed a new Phase 1 study (PF‑07328948), underscoring ongoing R&D investment and potential future catalysts from early‑stage programs. Pfizer’s New Phase 1 PF-07328948 Study Signals Ongoing Pipeline Investment
• Positive Sentiment: Some bullish commentary argues Pfizer is undervalued today and represents a long‑term buying opportunity given cash flow and dividend support. Prediction: In 5 Years, You’ll Wish You Bought Pfizer Stock Today
• Neutral Sentiment: Pfizer Limited (India) opened a window for dematerialisation of physical shares — an administrative item with limited direct impact on PFE ADR liquidity in the U.S. Pfizer Limited Opens Special Window for Dematerialisation of Physical Shares
• Neutral Sentiment: CEO Albert Bourla’s public comments about U.S./European research competitiveness are strategic/opinion‑level and may influence long‑term R&D policy discussion but not near‑term stock moves. Only one U.S. university ranks in the world’s top 10 in STEM. Pfizer’s CEO is calling for change
• Neutral Sentiment: Trading has also been tied to broader S&P 500 movement recently, suggesting some of the stock’s volatility is index/market driven rather than company‑specific. Pfizer Inc. (NYSE:PFE) Market Action Tied To S&P 500 Index Movement
• Negative Sentiment: Benzinga reports Pfizer and its COVID‑19 vaccine partner paused an updated‑shot trial — a near‑term execution risk that likely prompted downward pressure earlier in the week. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: Policy risk: reports of a potential Washington framework that could impose steep tariffs on drugmakers without pricing deals introduce regulatory uncertainty that could hit margins and valuation. Why Is Pfizer Stock Dropping Tuesday?
• Negative Sentiment: RBC Capital reaffirmed a sell rating and recent analyst negativity contributed to a near‑term pullback; sell‑side skepticism remains a headwind for sentiment. RBC Capital Reaffirms Their Sell Rating on Pfizer (PFE)

Pfizer Stock Performance

NYSE:PFE opened at $27.47 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $27.17 and a two-hundred day moving average price of $25.90. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $28.75. The company has a market capitalization of $156.21 billion, a P/E ratio of 20.20 and a beta of 0.43.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period last year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.